운할로페리돌과 아리피프라졸을 복용하는 조현병 환자에서의 운전능력 관련 정신운동수행
Psychomotor Performance Relevant to Driving Ability in Patients with Schizophrenia Treated with Haloperidol and Aripiprazole
3
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Objectives : This study aimed to compare psychomotor performance related with automobile driving in patients with schizophrenia under the treatment of a typical antipsychotic agent, haloperidol, or an atypical antipsychotic agent, aripiprazole. Methods : We evaluated driving ability of schizophrenia patients by using the cognitive perceptual assessment for driving (CPAD). Twelve patients receiving haloperidol monotherapy and 18 taking aripiprazole monotherapy participated in this study and the results of CPAD were compared with each other. Results : Of 30 participants, 15 (50%) of the patients passed the CPAD to be regarded as competent to drive, 3 (10%) of the patients failed the CPAD considered to be severely impaired. Controlling for sex, age, education, duration of illness, there were no significant differences in the CPAD results between two treatment groups. We observed a trend that patients who received aripiprazole showed a higher total score of the CPAD than haloperidol-treated patients (55.2±4.9 vs. 45.7±8.4, p=0.080). Conclusion : There were no significant differences in the psychomotor performance relevant to driving ability between haloperidol and aripiprazole groups. But our results suggest that aripiprazole might have the neurocognitive advantage over haloperidol. Future study with a large sample size and diverse antipsychotics is warranted.
Abstract
Objectives : This study aimed to compare psychomotor performance related with automobile driving in patients with schizophrenia under the treatment of a typical antipsychotic agent, haloperidol, or an atypical antipsychotic agent, aripiprazole. Methods : We evaluated driving ability of schizophrenia patients by using the cognitive perceptual assessment for driving (CPAD). Twelve patients receiving haloperidol monotherapy and 18 taking aripiprazole monotherapy participated in this study and the results of CPAD were compared with each other. Results : Of 30 participants, 15 (50%) of the patients passed the CPAD to be regarded as competent to drive, 3 (10%) of the patients failed the CPAD considered to be severely impaired. Controlling for sex, age, education, duration of illness, there were no significant differences in the CPAD results between two treatment groups. We observed a trend that patients who received aripiprazole showed a higher total score of the CPAD than haloperidol-treated patients (55.2±4.9 vs. 45.7±8.4, p=0.080). Conclusion : There were no significant differences in the psychomotor performance relevant to driving ability between haloperidol and aripiprazole groups. But our results suggest that aripiprazole might have the neurocognitive advantage over haloperidol. Future study with a large sample size and diverse antipsychotics is warranted.
참고문헌 (26)
- Velligan DI, "Cognitive dysfunction in schizophrenia and its importance to outcome: the place of atypical antipsychotics in treatment", J Clin Psychiatry, 60, pp.25~28 (1999)
- Nuechterlein KH, "Identification of separable cognitive factors in schizophrenia", Schizophr Res, 72, pp.29~39 (2004)
- Green MF., "What are the functional consequences of neurocognitive deficits in schizophrenia?", Am J Psychiatry, 153, pp.321~330 (1996)
- Marshall SC, "Finestone HM, et al. Predictors of driving ability following stroke: a systematic review", Top Stroke Rehabil, 14, pp.98~114 (2007)
- Koh ES, "Application of cognitive perceptual assessment for driving in patients with schizophrenia", Korean J Schizophr Res, 13, pp.133~140 (2010)
- Soyka M, "Effects of haloperidol and risperidone on psychomotor performance relevant to driving ability in schizophrenic patients compared to healthy controls", J Psychiatr Res, 39, pp.101~108 (2005)
- Brunnauer A, "Mobility behaviour of patients with mental illness", Dtsch Z Nervenheilkd, 27(suppl), pp.120~121 (2008)
- Edlund MJ, "Accidents among schizophrenic outpatients", Compr Psychiatry, 30, pp.522~526 (1989)
- Harvey PD, "Studies of cognitive change in patients with schizophrenia following novel antipsychotic treatment", Am J Psychiatry, 158, pp.176~184 (2001)
- Gallhofer B, "Cognitive dysfunction in schizophrenia: comparison of treatment with atypical antipsychotic agents and conventional neuroleptic drugs", Eur Neuropsychopharmacol, 6, pp.13~20 (1996)
- Grabe H, "The Influence of clozapine and typical neuroleptics on information processing of the central nervous system under clinical conditions in schizophrenic disorders: implications for fitness to drive", Neuropsychobiology, 40, pp.196~201 (1999)
- Kagerer S, "Effects of haloperidol and atypical neuroleptics on psychomotor performance and driving ability in schizophrenic patients", Neuropsychobiology, 47, pp.212~218 (2003)
- Brunnauer A, "Driving simulator performance and psychomotor functions of schizophrenic patients treated with antipsychotics", Eur Arch Psychiatry Clin Neurosci, 259, pp.483~489 (2009)
- American Psychiatric Association, "Diagnostic and Statistical Manual of Mental Disorders, 4th edition, text revision" (2000), American Psychiatric Press, Inc
- Kay SR, "The positive and negative syndrome scale (PANSS) for schizophrenia", Schizophr Bull, 13, pp.261~276 (1987)
- Chouinard G, "Manual for the extrapyramidal symptom rating scale (ESRS)", Schizophr Res, 76, pp.247~265 (2005)
- 이준욱, "뇌손상 장애인의 운전을 위한 인지-지각능력 평가 도구의 개발과 적용: '운전자 인지행동검사'와의 비교", Annals of Rehabilitation Medicine, 28(6), pp.523~531 (2004), 대한재활의학회
- Report on verification study of restandardization and predictive validation of driving aptitude test, "Kim MU", Seoul National University, ~ (2003)
- Engum ES, "Cognitive behavioral driver’s inventory", Cognit Rehabil, 6, pp.34~50 (1988)
- 최수원, "뇌손상 환자의 운전을 위한 인지 지각 능력 평가 도구의 적용-예비연구-", Annals of Rehabilitation Medicine, 32(3), pp.273~279 (2008), 대한재활의학회
- Brunnauer A, "The impact of antipsychotics on psychomotor performance with regards to car driving skills", J Clin Psychopharmacol, 24, pp.155~160 (2004)
- Burris KD, "Aripiprazole, a novel antipsychotic, is a high-affinity partial agonist at human dopamine D2 receptors", J Pharmacol Exp Ther, 302, pp.381~389 (2002)
- Jordan S, "The antipsychotic aripiprazole is a potent, partial agonist at the human 5-HT1A receptor", Eur J Pharmacol, 441, pp.137~140 (2002)
- Shapiro DA, "Aripiprazole, a novel atypical antipsychotic drug with a unique and robust pharmacology", Neuropsychopharmacology, 28, pp.1400~1411 (2003)
- Kern RS, "The neurocognitive effects of aripiprazole: an openlabel comparison with olanzapine", Psychopharmacology, 187, pp.312~320 (2006)
- Levoyer D, "Clinical impact of aripiprazole in patients suffering from schizophrenia", L’Encéphale, 33(3 Pt 1), pp.332~338 (2007)